Work

Hydroxyurea (hydroxycarbamide) in haemoglobin SC disease: Moving from therapeutic hesitation to evidence‐guided care

Year: 2026

Type: article

Abstract: Girard et al. report a retrospective, single-centre, real-world study evaluating hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease in Quebec. Hydroxyurea was associated with reduced vaso-occlusive crisis composite events, mostly mild adverse events and no observed hyperviscosity-related complications, while highlighting adherence and prescription-renewal barriers in routine care. Commentary on: Girard et al. Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec. Br J Haematol 2026; 209:1291-1300.

Source: British Journal of Haematology

DOI: 10.1111/bjh.70654

Author: Tahereh Setayesh

Institutions: Cincinnati Children's Hospital Medical Center, College of Charleston

Language: English

Topic: Hemoglobinopathies and Related Disorders

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,190